Naperville, IL -- (SBWIRE) -- 02/18/2014 -- Reportstack, provider of premium market research reports announces the addition of Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech market report to its offering
The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the preclinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter preclinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest preclinical agreements announced in the healthcare sector.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all preclinical stage partnering deals announced since 2009 including financial terms where available including over 2,000 links to online deal records of actual preclinical partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
For example, analyzing actual company deals and agreements allows assessment of the following:
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What are the precise rights granted or optioned?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
The initial chapters of this report provide an orientation of preclinical stage deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of why companies partner preclinical stage compounds/products.
Chapter 3 provides an overview of preclinical stage deals strategy and deal structure including numerous case studies. Chapter 4 provides an overview of the various payment strategies used in preclinical stage deals.
Chapter 5 provides a review of trends in preclinical stage deal making since 2009. Deals are listed by big pharma and big biotech dealmaking in preclinical stage, deal type, therapy type and technology type.
Chapter 6 provides a detailed analysis of preclinical stage payment terms including average headline, upfront, milestone and royalty rates for preclinical deals.
Chapter 7 provides a review of the leading preclinical stage deal by headline value.
Chapter 8 provides a comprehensive listing of the top 50 big pharma and top 50 big biotech companies with a brief summary followed by a comprehensive listing of preclinical stage deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 9 provides a comprehensive and detailed review of preclinical stage partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter 10 provides a comprehensive directory of preclinical stage partnering deals since 2009 organized by stage of development – preclinical.
The report also includes numerous tables and figures that illustrate the trends and activities in preclinical stage partnering and deal making since 2009.
In addition, a comprehensive appendix is provided organized by partnering company A-Z , deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of preclinical stage products and compounds.
Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech provides the reader with the following key benefits:
In-depth understanding of preclinical stage deal trends since 2009
Access to headline, upfront, milestone and royalty data
Analysis of the structure of preclinical stage agreements with numerous real life case studies
Detailed access to actual preclinical stage deals entered into by the leading fifty big pharma and big biotech companies
Insight into the terms included in a preclinical stage agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Preclinical Stage Partnering Terms and Agreements Terms and Agreements in Pharm and Biotech is intended to provide the reader with an in-depth understanding and access to preclinical stage deal trends and structure of deals entered into by leading companies worldwide.
Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech includes:
Trends in preclinical stage dealmaking in the biopharma industry since 2009
Analysis of preclinical stage deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life preclinical stage deals
Access to over 2,000 preclinical stage deals
The leading preclinical stage deals by value since 2009
Most active preclinical stage dealmakers since 2009
The leading preclinical stage partnering resources
In Preclinical Stage Partnering Terms and Agreements in Pharm and Biotech, the available contracts are listed by:
Stage of development at signing
Specific therapy target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
To view the table of contents for this market research report please visit